MoCD Type A is an extremely uncommon and progressive illness that affects less than 150 individuals worldwide, with a four-year median survival.
NULIBRY is a first-in-class cPMP substrate replacement medication authorised by the US Food and Drug Administration (USFDA) in 2021 to lower the risk of mortality in MoCD Type A patients. Following the EC's decision, NULIBRY is the first and only authorised medication for MoCD Type A in the European Union (EU).
Sentynl acquired the global rights to NULIBRY in March 2022 and is responsible for the continued development and marketing of NULIBRY in the United States, as well as the development, production, and commercialization of fosdenopterin globally.
Sentynl and BridgeBio share development commitments through the clearance of NULIBRY's regulatory submission with the Israeli Ministry of Health and the marketing authorization application under accelerated evaluation with the European Medicines Agency (EMA).
The EC approval comes on the heels of a positive opinion issued by the European Committee for Medicinal Products for Human Use (CHMP) in July 2022, which was supported by data from three clinical trials that demonstrated the efficacy of NULIBRY for the treatment of patients with MoCD Type A when compared to data from a natural history study.
At around 1.27 PM, Zydus Lifesciences was trading at Rs367.45 down by 0.89% from its previous closing of Rs370.75 on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.